MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
71.73
+0.76
+1.07%
After Hours: 71.99 +0.26 +0.36% 17:13 04/11 EDT
OPEN
71.11
PREV CLOSE
70.97
HIGH
71.95
LOW
68.70
VOLUME
782.19K
TURNOVER
0
52 WEEK HIGH
98.40
52 WEEK LOW
55.02
MARKET CAP
3.40B
P/E (TTM)
-13.6198
1D
5D
1M
3M
1Y
5Y
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
NASDAQ · 1d ago
Analyst Ratings For Axsome Therapeutics
20 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM) in the last three months. The 12-month price targets assessed by analysts have an average target of $130.3. The company is developing novel therapies for the management of central nervous system disorders.
Benzinga · 2d ago
ClearBridge Small Cap Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Small Cap Strategy underperformed the benchmark Russell 2000 Index in the first quarter by 177 bps. The two largest-capitalization stocks in the index - Super Micro Computer and MicroStrategy - contributed to the index's performance. Super Micro is now the largest position ever in the Russell 2000 index.
Seeking Alpha · 2d ago
Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)
TipRanks · 2d ago
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Axsome Therapeutics, Inc. Will report its financial results for the first quarter of 2024 on May 6, 2024. Axsome is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders. The company will host a conference call to discuss these results.
Barchart · 2d ago
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanks · 3d ago
More
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.